Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
gptkb:J05AP55
|
| gptkbp:brand |
gptkb:Zepatier
|
| gptkbp:CASNumber |
1248320-38-2
|
| gptkbp:combines |
gptkb:grazoprevir
|
| gptkbp:developedBy |
gptkb:Merck_&_Co.
|
| gptkbp:hasMolecularFormula |
C49H55N9O7
|
| gptkbp:hasSMILES |
CC(C)C[C@@H](C(=O)N1CCN(CC1)C2=NC3=CC=CC=C3N=C2N4CCN(CC4)C(=O)C5=CC=CC=C5)NC(=O)C6=CC=CC=C6
|
| https://www.w3.org/2000/01/rdf-schema#label |
elbasvir
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
NS5A inhibitor
|
| gptkbp:pregnancyCategory |
B1 (Australia)
N (US) |
| gptkbp:PubChem_CID |
gptkb:CHEMBL3137347
67505836 DB11574 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
fatigue headache elevated liver enzymes |
| gptkbp:target |
NS5A protein of HCV
|
| gptkbp:UNII |
6J9B8T8V8I
|
| gptkbp:usedFor |
treatment of hepatitis C
|
| gptkbp:bfsParent |
gptkb:Zepatier
|
| gptkbp:bfsLayer |
6
|